|本期目录/Table of Contents|

[1]郑翠霞,崔绘丽,吴栋云,等.新型冠状病毒肺炎恢复期血浆治疗对重型患者活动耐力的影响[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):487-491.[doi:10.3969/j.issn.1672-271X.2020.05.008]
　ZHENG Cui-xia,7,CUI Hui-li,et al.Novel coronavirus pneumonia recovery plasma treatment on heavy patient’s activity endurance influence[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(5):487-491.[doi:10.3969/j.issn.1672-271X.2020.05.008]
点击复制

新型冠状病毒肺炎恢复期血浆治疗对重型患者活动耐力的影响()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第22卷
期数:
2020年5期
页码:
487-491
栏目:
临床研究
出版日期:
2020-09-09

文章信息/Info

Title:
Novel coronavirus pneumonia recovery plasma treatment on heavy patient’s activity endurance influence
作者:
郑翠霞; 崔绘丽; 吴栋云; 吴媛媛; 冯安妮; 黄芸芸; 倪娟
作者单位：210002南京，东部战区总医院秦淮医疗区消化科（郑翠霞、崔绘丽），产科(吴栋云)，胸外科(吴媛媛)，放疗科(冯安妮)，普外科(黄芸芸)，护理部(倪娟）；430100武汉，武汉火神山医院感染四科一病区（郑翠霞、吴栋云、吴媛媛、冯安妮、黄芸芸、倪娟）
Author(s):
ZHENG Cui-xia1; 7; CUI Hui-li1;  WU Dong-yun2; 7;  WU Yuan-yuan3; 7;  FENG An-ni4; 7;  HUANG Yun-yun5; 7;  NI Juan6; 7
(1. Department of Gastroenterology, 2. Department of Obstetrics, 3. Department of Thoracic Surgery, 4. Department of Radiotherapy, 5. Department of General Surgery,6. Department of Nursing，Qinhuai Medical Area, General Hospital of Eastern Theater Command，PLA，Nangjing 210002，Jiangsu，China; 7. 1st Ward, Four Departments of Infection, Wuhan Huoshenshan Hospital，Wuhan 430100，Hubei，China)
关键词:
新型冠状病毒肺炎; 恢复期血浆; 活动耐力; 血氧饱和度; 心率
Keywords:
COVID-19;  convalescent plasma therapy;  activity endurance;  oxygen saturation;  heart rate
分类号:
R473；R56
DOI:
10.3969/j.issn.1672-271X.2020.05.008
文献标志码:
A
摘要:
目的探讨新型冠状病毒肺炎恢复期血浆治疗对重型患者活动耐力的影响。方法选取2020年3月2日至3月27日在武汉火神山医院感染四科一病区住院的新型冠状病毒肺炎重型患者57例为研究对象，年龄27～91（65.8±4.3）岁。患者采取一般治疗、抗病毒治疗及中药汤剂治疗等，同时使用新型冠状病毒肺炎恢复期患者检测具有高倍抗体的血浆治疗。观察患者血浆治疗前后心率(HR)、呼吸(R)、血氧饱和度(SpO2)、红细胞(RBC)、白细胞(WBC)、血小板(PLT)、凝血酶原时间(PT)及乳酸脱氢酶（LDH）情况，同时观察患者活动耐量及6 min步行试验情况。结果患者输注血浆后HR、R、PT及LDH均低于输血浆前，但SpO2、WBC、RBC、PLT均高于输血浆前，差异均有统计学意义(P＜0.01)。治疗前患者活动耐量轻微影响15例(占26.3%)，严重影响14例(占24.6%)，非常严重影响6例(占10.5%)；输注血浆后3 d患者活动耐量轻微影响24例(占42.1%)，严重影响7例(占12.3%)，非常严重影响2例(占3.5%)，与输注血浆前比较活动耐量明显增加(P<0.01)。治疗前6 min步行试验，<300 m的患者28例(占49.1%)，>500 m的患者只有1例(占1.8%)；输注血浆后<300 m的患者17例(占29.8%)，>500 m增至8例(占14.0%)，治疗前后比较差异有统计学意义(P<0.01)。结论新型冠状病毒肺炎重型患者输注康复者血浆后能增强机体抵抗力及活动耐力，增加凝血因子及促进肝功能修复。
Abstract:
ObjectiveTo investigate the novel coronavirus pneumonia recovery period plasma treatment on the heavy patient’s activity endurance.MethodsA total of 57 novel coronavirus pneumonia patients with severe pneumonia were selected from four to one ward in Wuhan, March 2, 2020 to March 27th. The age of the patients was 27-91 (65.8±4.3) years. Patients were treated with general treatment, antiviral treatment and TCM decoction, while patients in the convalescent stage of COVID-19 were tested for plasma treatment with high-power antibodies. Heart rate (HR), respiration (R), oxygen saturation (SpO2), red blood cell (RBC),white blood cell (WBC), platelet (PLT), prothrombin time (PT) and lactate dehydrogenase (LDH) were observed before and after plasma treatment. Meanwhile, activity tolerance and 6 min walking test were observed.ResultsThe HR, R, PT and LDH after plasma transfusion were all lower than those before plasma transfusion, However, the SpO2, WBC, RBC and PLT were all higher than those before plasma transfusion, with statistically significant differences (P<0.01). Before treatment, activity tolerance was slightly affected in 15 cases (26.3%), severely affected in 14 cases (24.6%), and seriously affected in 6 cases (10.5%). After plasma infusion, activity tolerance of 24 patients (42.1%) was slightly affected, 7 patients (12.3%) were seriously affected, and 2 patients (3.5%) were seriously affected. The difference before and after treatment was statistically significant (P<0.05), and activity tolerance was significantly increased compared with that before plasma infusion. In the 6 min walking test before treatment, there were 28 patients (49.1%) with <300 m and only 1 patient (1.8%) with >500 m. In the 6 min walking test after plasma infusion, there were only 17 patients (29.8%) with <300 m, and 8 patients (14.0%) with >500 m. The difference was statistically significant before and after treatment (P<0.05).ConclusionIn severe patients with COVID-19, plasma infusion can enhance the body’s resistance and activity endurance, increase coagulation factors and promote liver function repair.

参考文献/References:

[1]中华人民共和国国家卫生健康委员会．新型冠状病毒感染的肺炎诊疗方案（试行第六版）[EB/OL]. (2020-01-27)
[2020-01-30]．http：//www.nhc.gov.cn/xcs/zhengcwj/202001/4294563ed35b43209b31739bd0785e67.shtml.
[2]杨晓明，侯继峰．康复期血浆应用于急性病毒性传染病现状及其治疗新型冠状病毒肺炎前景［J］．中国生物制品学杂志，2020，33(3)：241-245.
[3]Leider JP, Brunker PA, Ness PM. Convalescent transfusion for pandemic influenza：preparing blood banks for a new plasma product［J］. Transfusion，2010，50（6）：1384-1398.
[4]Arabi Y, Balkhy H, Hajeer AH，et al. Feasibility，safety，clinical，and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection：a study protocol［J］. Springerplus，2015，4:709.
[5]黄利民，张炜，孙兆瑞，等．氨溴索雾化吸入治疗老年慢性支气管炎疗效及安全性的系统评价［J］．东南国防医药，2020，22(2)：165-171.
[6]王婷婷，韩 影，高芳芳，等．不同保存时间的血浆及血清中外泌体生物学特性的对比[J]．医学研究生学报，2019，32 (7):705-709.
[7]Gupta N，Pinto LM，Morogan A，et al. The COPD assessmenttest: a systematic review[J]. Eur Respir J，2014，44（4）:873-884.
[8]阎炜，余静．6分钟步行试验：评估慢性心衰患者心功能的一种简单客观方法[J]．心血管病学进展, 2002，23(2): 86-88.
[9]莫介程，叶桂成，孙振永．输血浆治疗对纠正重症恙虫病患者内环境失衡的效果[J]．深圳中西医结合杂志，2019，29(17)：148-149.
[10]李营，张树超，张少强，等．康复者血浆治疗新型冠状病毒肺炎疗效分析1例[J/OL]．临床输血与检验.（2020-04-16）．http://kns.cnki.net/kcms/detail/34.1239.R.20200415.1851.002.html.
[11]姚亚淑，新越．新鲜血浆治疗小儿肺炎的疗效分析[J]．生物技术世界，2015，22(8)：69.
[12]赵军宁，戴瑛，华桦，等．治疗新冠病毒肺炎（COVID-19）中药“药理谱-云”特点与有效性评价要素［J/OL］．中药药理与临床．DOI：10.13412/j.cnki.zyyl.20200313.002.
[13]朱春雾，王海南，张亚蕾，等．140例中药肝损伤病例的临床特征分析［J］．肝脏，2019，4(10)：362-364.
[14]王志伟，李文静，孙永利，等．小剂量美罗华联合冰冻血浆治疗肺炎性血小板减少症的临床价值分析[J]. 现代中西医结合杂志，2017，26(8)：872-873.
[15]杨晓明，侯继峰．康复期血浆应用于急性病毒性传染病现状及其治疗新型冠状病毒肺炎前景[J]. 中国生物制品学杂志，2020，33(3)：241-245.
[16]白文娣，蔡微，陈仕锋，等．以新型冠状病毒肺炎为例浅析血浆疗法的现况及发展[J/OL]．病毒学报.（2020-03-27）．DOI：10.13242/j.cnki.bingduxuebao.003672.

相似文献/References:

[1]沈国栋,谭伟龙.新型冠状病毒肺炎流行期间军队医疗机构面临的采供血和输血风险与安全防护[J].医学研究与战创伤救治(原医学研究生学报),2020,22(4):342.[doi:10.3969/j.issn.1672-271X.2020.04.002]
　SHEN Guo-dong,TAN Wei-long.Risk and safety of blood collection and transfusion in military medical institutions during COVID-19 epidemic[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(5):342.[doi:10.3969/j.issn.1672-271X.2020.04.002]
[2]杨艳,王佳佳,汪文妮,等.新型冠状病毒肺炎期间军队医院老年病房的防控管理[J].医学研究与战创伤救治(原医学研究生学报),2020,22(4):434.[doi:10.3969/j.issn.1672-271X.2020.04.024]
[3]王颖,钟勇,金涛,等.新型冠状病毒肺炎期间做好军队老干部防疫工作的实践与思考[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):552.[doi:10.3969/j.issn.1672-271X.2020.05.026]
[4]陈伟,施涛,王少华,等.新型冠状病毒肺炎疫情期间医院发热诊区的军队人员管理实践[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):555.[doi:10.3969/j.issn.1672-271X.2020.05.027]
[5]金娥,陈珺,陈丽珍,等.新型冠状病毒肺炎疫情期间血液净化室防控实践[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):558.[doi:10.3969/j.issn.1672-271X.2020.05.028]
[6]周莉萍,黄迎春,浦嘉丽,等.思维导图在新型冠状病毒肺炎疫情期间辅助护士优化预检筛查流程中的应用[J].医学研究与战创伤救治(原医学研究生学报),2020,22(6):658.[doi:10.3969/j.issn.1672-271X.2020.06.023]
[7]袁力,陈醒,孙伟,等.援鄂医疗队在抗击新型冠状病毒肺炎中的药品保障实践与思考[J].医学研究与战创伤救治(原医学研究生学报),2020,22(6):661.[doi:10.3969/j.issn.1672-271X.2020.06.024]
[8]刘颖,伏海燕,李美玲,等.新型冠状病毒肺炎疫情期间医院生殖中心防控管理探讨[J].医学研究与战创伤救治(原医学研究生学报),2020,22(6):664.[doi:10.3969/j.issn.1672-271X.2020.06.025]
[9]赵承奇,靳增华,王雪芬,等.新型冠状病毒肺炎治疗药物的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(01):58.[doi:10.3969/j.issn.1672-271X.2021.01.001]
　ZHAO Cheng-qi,JIN Zeng-hua,WANG Xue-fen,et al.Currentstatus andadvances for development of drugs to treat coronavirus disease 2019[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(5):58.[doi:10.3969/j.issn.1672-271X.2021.01.001]
[10]蔡玉龙,刘炯,夏国际,等.托珠单抗治疗高龄新型冠状病毒肺炎患者的临床疗效[J].医学研究与战创伤救治(原医学研究生学报),2021,23(01):75.[doi:10.3969/j.issn.1672-271X.2021.01.001]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2020-09-09